Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: EC:2.7.7.8 (
polynucleotide phosphorylase
)
723
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Nuclear existence of
epidermal growth factor receptor
(
EGFR
) has been documented for more than two decades. Resistance of cancer to radiotherapy is frequently correlated with elevated
EGFR
expression, activity, and nuclear translocation. However, the role of nuclear
EGFR
(nEGFR) in radioresistance of cancers remains elusive. In the current study, we identified a novel nEGFR-associated protein,
polynucleotide phosphorylase
(
PNPase
), which possesses 3' to 5' exoribonuclease activity toward c-MYC mRNA. Knockdown of
PNPase
increased radioresistance. Inactivation or knock-down of
EGFR
enhanced
PNPase
-mediated c-MYC mRNA degradation in breast cancer cells, and also increased its radiosensitivity. Interestingly, the association of nEGFR with
PNPase
and DNA-dependent protein kinase (DNAPK) increased significantly in breast cancer cells after exposure to ionizing radiation (IR). We also demonstrated that DNAPK phosphorylates
PNPase
at Ser-776, which is critical for its ribonuclease activity. The phospho-mimetic S776D mutant of
PNPase
impaired its ribonuclease activity whereas the nonphosphorylatable S776A mutant effectively degraded c-MYC mRNA. Here, we uncovered a novel role of nEGFR in radioresistance, and that is, upon ionizing radiation, nEGFR inactivates the ribonuclease activity of
PNPase
toward c-MYC mRNA through DNAPK-mediated Ser-776 phosphorylation, leading to increase of c-MYC mRNA, which contributes to radioresistance of cancer cells.
...
PMID:Nuclear EGFR suppresses ribonuclease activity of polynucleotide phosphorylase through DNAPK-mediated phosphorylation at serine 776. 2281 74
The
epidermal growth factor receptor
(
EGFR
) is a well-studied receptor-tyrosine kinase that serves vital roles in regulation of organ development and cancer progression.
EGFR
not only exists on the plasma membrane, but also widely expressed in the nucleus, endosomes, and mitochondria. Most recently, several lines of evidences indicated that autophagy is regulated by
EGFR
in kinase-active and -independent manners. In this review, we summarized recent advances in our understanding of the functions of different subcellularly located
EGFR
on autophagy. Specifically, plasma membrane- and cytoplasm-located
EGFR
(pcEGFR) acts as a tyrosine kinase to regulate autophagy via the PI3K/AKT1/mTOR, RAS/MAPK1/3, and STAT3 signaling pathways. The kinase-independent function of pcEGFR inhibits autophagy by maintaining SLC5A1-regulated intracellular glucose level. Endosome-located
EGFR
phosphorylates and inhibits Beclin1 to suppress autophagy, while kinase-independent endosome-located
EGFR
releases Beclin1 from the Rubicon-Beclin1 complex to increase autophagy. Additionally, the nuclear
EGFR
activates PRKDC/
PNPase
/MYC signaling to inhibit autophagy. Although the role of mitochondria-located
EGFR
in autophagy is largely unexplored, the production of ATP and reactive oxygen species mediated by mitochondrial dynamics is most likely to influence autophagy.
...
PMID:The roles of subcellularly located EGFR in autophagy. 2842 83